ARTICLE | Product Development

ESMO shifts the HER2 antibody landscape

How next-gen antibody innovation is driving advances in HER2-positive cancers

By Lauren Melissen, senior editor

September 24, 2021 11:01 PM GMT

Access this Article

Request a Trial

Purchase This Article

Subscribers Log in

BCIQ Company Profiles

Daiichi Sankyo Co. Ltd.

AstraZeneca plc

Shanghai Miracogen Inc.

Alphamab Oncology Ltd.

BCIQ Target Profiles

Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)

BCIQ Company Profiles

Daiichi Sankyo Co. Ltd.

AstraZeneca plc

Shanghai Miracogen Inc.

Alphamab Oncology Ltd.

BCIQ Target Profiles

Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)